New RNAi Approach for In Vivo Therapeutic Silencing of MicroRNAs is Demonstrated by Alnylam and Rockefeller University Scientists.

Publication: Business Wire

Bookmark this article Print this article Link to this article Email this article Digg It! Add to del.icio.us RSS

COPYRIGHT 2005 Business Wire

CAMBRIDGE, Mass. -- Findings Published in Nature Show Potential of Targeting MicroRNAs to Treat Diseases

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the publication of a novel approach to regulate gene expression through the silencing of microRNAs (miRNAs). miRNAs have been shown to regulate a large number of genes in the human genome through the RNAi pathway. Many of these miRNAs are believed to be involved in disease processes. In a paper published yesterday in Nature, scientists from The Rockefeller University and Alnylam describe the rational design of a potential new class of chemically modified RNA-based drugs, called 'antagomirs', that specifically silence miRNAs across multiple tissue types following therapeutically relevant administration in animals. We believe this research creates the opportunity to design antagomirs that target miRNAs in the context of human diseases, such as cancer and viral infection.

"miRNAs are critical for the control of gene expression in all living cells, and appear to play an important role in both normal...

Read the full article for free courtesy of your local library.